Edwards Lifesciences (EW) Net Income towards Common Stockholders (2009 - 2025)

Edwards Lifesciences' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $27.0 million for Q4 2025.

• In Q4 2025, Net Income towards Common Stockholders fell 31.3% year-over-year to $27.0 million; the TTM figure through Mar 2026 stood at $20.6 million (down 99.25% YoY), while the FY2025 annual figure was $13.4 million, down 99.52% from the prior year.
• Net Income towards Common Stockholders was $27.0 million for Q4 2025 at Edwards Lifesciences, up from -$2.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $2.7 billion in Q3 2024 to a low of -$7.2 million in Q1 2025.
• Historically, Net Income towards Common Stockholders has averaged $314.6 million across 5 years, with a median of $194.7 million in 2021.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders jumped 5447.75% in 2024, then sank 540.0% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $335.3 million in 2021, then advanced by 18.82% to $398.4 million in 2022, then tumbled by 90.81% to $36.6 million in 2023, then rose by 7.38% to $39.3 million in 2024, then plunged by 31.3% to $27.0 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at $27.0 million (Q4 2025), -$2.0 million (Q3 2025), and -$4.4 million (Q2 2025), per Business Quant data.